Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic, Cognitive, and Neurodegenerative Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HSD11B1 drug discovery. The following table summarizes available reagents and related network targets:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HSD11B1 Recombinant Protein (WT and Somatic Mutant Variants) - High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed with native glycosylation. | View HSD11B1 Products |
| Counter-Screen | HSD11B2 Isoform Protein - For selectivity assays vs renal paralog. High purity, identical expression system. | View HSD11B2 Products |
| Gene Delivery | HSD11B1 Promise-ORF / Lentivirus - Full-length ORF for stable cell line construction (HepG2/3T3-L1). HEK293 packaged, Puromycin selection. | View HSD11B1 Products |
| Benchmark Ab | Anti-HSD11B1 Benchmark Antibody - Recombinant positive control for Western blot and IHC. | View HSD11B1 Products |
| Validator | HSD11B1 siRNA Set - For knockdown verification and assay specificity in adipocytes and hepatocytes. | View HSD11B1 Products |
| Related Target A | HSD11B2 - Paralog selectivity counter-screening; essential for isoform-specific inhibitor programs. | View HSD11B2 Products |
| Related Target B | NR3C1 (Glucocorticoid Receptor) - Downstream pathway partner for functional cortisol signaling studies. | View NR3C1 Products |
| Related Target C | CYP11B1 - Steroidogenesis enzyme for expanded selectivity panel. | View CYP11B1 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Counter-Screening (HSD11B1 vs HSD11B2) | Purified human HSD11B1 and HSD11B2 proteins from identical HEK293 expression systems for direct kinetic comparison; mass spectrometry and sequence verified. |
| Enzymatic Assay Reliability | High purity (>95%), endotoxin controlled (<1EU/ug) recombinant proteins with validated NADPH/NADP+ cofactor regeneration system. |
| Lack of Positive Controls | Clinical benchmark antibodies included for assay standardization and normalization. |
| False Positive Reduction | Validated siRNA set (3 independent targets) for specificity checks in cell-based assays. |
| Compound Permeability | Full-length protein includes native N-terminal membrane anchor, enabling liposome reconstitution and permeability assays. |
| Tissue-Specific Activity | Lentivirus-mediated stable cell lines (HepG2 for liver, 3T3-L1 for adipose) allow cell-type specific activity testing. |
Live HSD11B1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HSD11B1 therapeutics has experienced a strategic pivot over the past decade. Early-generation small molecules from AstraZeneca (AZD8329), Boehringer Ingelheim (BI 1414961), and Incyte faced Phase II failures due to systemic HPA axis activation and insufficient efficacy in metabolic indications (Type 2 Diabetes, Obesity). Consequently, the field is shifting toward tissue-restricted strategies to mitigate mechanism-based toxicities.
Major emerging directions include:
- Liver-targeted inhibitors: High Point Pharma (HSD-244) and HighTide Therapeutics aim to achieve local glucocorticoid modulation in NASH without systemic side effects.
- CNS-penetrant compounds: Actinogen Medical (Xanamem) targets Alzheimer's disease and cognitive impairment by reducing neuroinflammation via brain cortisol regulation.
- Antisense oligonucleotides (ASOs): Ionis Pharmaceuticals is exploring ASO-mediated HSD11B1 knockdown for metabolic syndrome, offering tissue-specific delivery.
- Allosteric modulators and PROTACs: Academic institutions are developing subfamily-selective allosteric inhibitors and targeted protein degraders to achieve greater specificity and avoid HPA axis disruption.
The next wave of R&D will emphasize exquisite selectivity over the renal paralog HSD11B2 (>100-fold window), tissue-specific delivery, and combination therapies with GLP-1 or FXR agonists for NASH. A somatic mutation (breast cancer sample, UniProt VAR_035845) has been identified, and mutant recombinant proteins are available for mechanistic studies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (CNS) | AstraZeneca, Incyte, Actinogen Medical | Alzheimer's Disease, Cognitive Impairment | Selectivity Assay (Need High-Purity WT vs HSD11B2 Proteins) |
| Small Molecule Inhibitor (Liver-Targeted) | High Point Pharma, HighTide Therapeutics | NASH, Type 2 Diabetes, Metabolic Dysfunction | Enzymatic Activity Assay (Need high-purity active recombinant enzyme with NADPH regeneration) |
| Antisense Oligonucleotide | Ionis Pharmaceuticals | Obesity, Metabolic Syndrome | Knockdown Validation (Need siRNA controls for specificity) |
| Allosteric Modulator | Academic Institutions | Metabolic Disease | Conformational Binding Assay (Need full-length native protein with membrane anchor) |
| Gene Therapy / PROTAC | Early Stage Academics | Glaucoma, Osteoporosis | Degradation Validation (Need HEK293 Expressed Targets & siRNA) |
Key Mutation Insights
A validated somatic mutation in HSD11B1 (breast cancer sample, UniProt VAR_035845) has been cataloged. TarMart supplies recombinant mutant protein to support structure-function studies and drug resistance mechanism investigations.